EUVIMEDEUVIMED entdecken
Netzwerk-Metaanalyse

Value and usability of unpublished data sources for systematic reviews and network meta-analyses

Nicholas James Anthony Halfpenny, Joan Mary Quigley, Juliette Catherine Thompson, David Alexander Scott

Evidence Based Medicine · 2016-12 · 21 (6) · 208-213

DOI: 10.1136/ebmed-2016-110494 ↗

Kurz gefasst

Netzwerk-Metaanalyse in der Zeitschrift Evidence Based Medicine, online erschienen am 29.09.2016. Verfasst von Nicholas James Anthony Halfpenny und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Economics & Epidemiology, ICON plc, Abingdon, Oxon, UK. Hauptthemen laut MEDLINE: Clinical Trials as Topic, Meta-Analysis as Topic, Review Literature as Topic. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Peer-reviewed publications and conference proceedings are the mainstay of data sources for systematic reviews and network meta-analyses (NMA), but access to informative unpublished data is now becoming commonplace. To explore the usefulness of three types of ‘grey’ literature-clinical trials registries, clinical study reports and data from regulatory authorities-we conducted four case studies. The reporting of outcome data in peer-reviewed publications, the clinical trials registries and the clinical study reports for two clinical trials—one in melanoma, one in juvenile idiopathic arthritis (JIA)—was examined. In addition, we assessed the value of including unpublished data from the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) in evidence syntheses of hepatitis C virus (HCV) and chronic obstructive pulmonary disease (COPD), respectively. For the clinical trials in melanoma and JIA, we identified outcome parameters on ClinicalTrials.gov additional to those reported in the peer-reviewed publications: subgroup data and additional efficacy end points/extended follow-up, respectively. The clinical study report also provided results for several subgroups unavailable elsewhere. For HCV and COPD, additional outcome data were obtained from the EMA European Public Assessment Report (EPAR) and the FDA, respectively, including data on subgroups and mortality. We conclude that data from these grey literature sources have the potential to influence results of systematic reviews and NMAs, and may thus have implications for healthcare decisions. However, it is important to consider carefully the availability, reliability and consequent usability of these data sources in systematic reviews and NMAs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials as TopicMeta-Analysis as TopicReview Literature as TopicHumansInformation Storage and RetrievalPublicationsRegistriesReproducibility of ResultsUnited StatesUnited States Food and Drug Administration

Stichwörter der Autor:innen

HEALTH ECONOMICSSTATISTICS & RESEARCH METHODS

Autor:innen und Institutionen

  • Department of Health Economics & Epidemiology, ICON plc, Abingdon, Oxon, UK.

Zitieren

APA

Halfpenny, N. J., Quigley, J. M., Thompson, J. C., & Scott, D. A. (2016). Value and usability of unpublished data sources for systematic reviews and network meta-analyses. Evidence Based Medicine, 21(6), 208-213. https://doi.org/10.1136/ebmed-2016-110494

Vancouver

Halfpenny NJ, Quigley JM, Thompson JC, Scott DA. Value and usability of unpublished data sources for systematic reviews and network meta-analyses. Evidence Based Medicine. 2016;21(6):208-213. doi:10.1136/ebmed-2016-110494

BibTeX
@article{Halfpenny2016,
  author = {Halfpenny, Nicholas James Anthony and Quigley, Joan Mary and Thompson, Juliette Catherine and Scott, David Alexander},
  title = {Value and usability of unpublished data sources for systematic reviews and network meta-analyses},
  journal = {Evidence Based Medicine},
  year = {2016},
  volume = {21},
  number = {6},
  pages = {208--213},
  doi = {10.1136/ebmed-2016-110494}
}
Kostenlos starten →